title: Chemical synoviorthesis for hemophilic synovitis.
abstract: For many years, Rifampicin has been used empirically for the treatment of hemophilic chronic synovitis with encouraging results. A study was performed in which Rifampicin was shown to reduce the inflammation of joints affected by hemophilic synovitis. A clinical study was performed on 48 hemophilic patients (48 joints). Seventeen elbows, eight knees, and 23 ankles were treated. The mean age of the patients was 6 years (range, 4-23 years) and the mean followup was 29 months (range, 24-53 months). Overall, 40 excellent results and eight good results were obtained. The average number of weekly injections of Rifampicin was 3.06 (range, 1-10 injections). Eight patients experienced pain on the first injection, which subsided gradually with the subsequent procedures. Synoviorthesis with Rifampicin seems to be a good method for the treatment of hemophilic synovitis, especially in small joints (elbows and ankles) and in younger children.
authors.affiliation: Hemophilia Foundation, Buenos Aires, Argentina.
authors.forename: H A
authors.initials: HA
authors.lastname: Caviglia
authors.forename: F
authors.initials: F
authors.lastname: Fernández-Palazzi
authors.forename: E
authors.initials: E
authors.lastname: Maffei
authors.forename: G
authors.initials: G
authors.lastname: Galatro
authors.forename: A
authors.initials: A
authors.lastname: Barrionuevo
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000818:Animals; D000843:Ankle Joint / Q000187:drug effects; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018771:Arthralgia / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004195:Disease Models, Animal; D004551:Elbow Joint / Q000187:drug effects; D005500:Follow-Up Studies; D005544:Forecasting; D006395:Hemarthrosis / Q000209:etiology; D006467:Hemophilia A / Q000150:complications*; D002836:Hemophilia B / Q000150:complications; D006801:Humans; D007270:Injections, Intra-Articular / Q000009:adverse effects; D007719:Knee Joint / Q000187:drug effects; D016015:Logistic Models; D008297:Male; D011817:Rabbits; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013585:Synovitis / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D012293:Rifampin